~~<i id='3697B8590D'><strike id='3697B8590D'><tt id='3697B8590D'><pre id='3697B8590D'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：knowledge 2025-10-03 00:47:01 Page View：72

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Readers respond to H5N1 and livestock movements, and more
Next article： Sports medicine is finally prioritizing gender equality

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

Anxious about a speech? A startup wants you to pop a minty cardiac drug

APSTockThepillworkslikemagic,peoplewho’veuseditsay,toquelltheiranxietyaroundpublicspeaking.Fordecade

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

Legitimacy of 'customer' in Supreme Court gay rights case raises ethical, legal flags

3:30FILE-PeopleonbothsidesofthedebaterallyoutsidetheSupremeCourtinWashington,Monday,Dec.5,2022.Inade